Combination therapy for cancer
AssigneeUnited Arab Emirates University
InventorAmr Amin
Life of this patent
Estimating the term…
Abstract
Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods include administering to the subject a first amount of safranal or a pharmaceutically acceptable pro-drug thereof and administering to the subject a second amount of a TOP1 inhibitor. In some embodiments, the TOP1 inhibitor is irinotecan, topotecan, camptothecin, lamellarin D, and/or combinations thereof.
Claims3
A method of treating, suppressing, or reducing the severity of hepatocellular carcinoma in a subject, the method comprising the steps of:
- administering to the subject a composition comprising safranal or a pharmaceutically acceptable pro-drug thereof, wherein the pro-drug is selected from the group consisting of:
- a safranal salt, hemiacetal, acetal, thioacetal, silyether, tautomer, and combinations thereof, and a pharmaceutically acceptable carrier;
- and then
- administering to the subject topotecan in an amount ranging from 0.1:1 to 10:1 by weight, with respect to the content of the safranal of the composition;
- wherein the safranal or its pro-drug is administered first to sensitize the hepatocellular carcinoma cells prior to exposure to the topotecan, and the topotecan is administered second, and
- wherein the safranal or its pro-drug is administered in a therapeutically effective amount sufficient to enhance cytotoxic effects of the topotecan on the hepatocellular carcinoma cells by reducing the IC50 of the topotecan by a sensitization factor of at least 73.
A therapeutic combination of drugs for the treatment of hepatocellular carcinoma, the combination comprising:
- safranal or a pharmaceutically acceptable pro-drug thereof, wherein the pro-drug is selected from the group consisting of:
- a safranal salt, hemiacetal, acetal, thioacetal, silylether, tautomer, and combinations thereof;
- a pharmaceutically acceptable carrier;
- and
- topotecan,
- wherein the amount of the topotecan is 0.1:1 to 10:1 by weight, with respect to the content of the safranal of the therapeutic combination, and
- wherein the safranal or its pro-drug and the topotecan are in separate pharmaceutical compositions and the safranal or its pro-drug is present in a therapeutically effective amount sufficient to reduce the IC50 of the topotecan against hepatocellular carcinoma cells by a sensitization factor of at least 73.
Dependencies are inferred from the claim text.